SEC Form 4 · accession 0001209191-19-003997
ANAPTYSBIO, INC · ANAB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hamza Suria
Officer — President, CEO · Director
Period of report
Jan 14, 2019
Accepted (ET)
Jan 16, 2019 · 7:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001370053
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 14, 2019 | M | 40,000 | $1.12 | A | 70,064 | D | |
| Common StockF2 | Jan 14, 2019 | S | 27,760 | $70.6494 | D | 42,304 | D | |
| Common StockF3 | Jan 14, 2019 | S | 12,240 | $71.1033 | D | 30,064 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F5,F4 | $1.12 | Jan 14, 2019 | M | 40,000 | D | — | Jan 31, 2022 | Common Stock | 40,000 | 89,284 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The stock option is fully vested and immediately exercisable.
- F5In addition to the remaining options to purchase 89,284 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 705,554 shares of common stock, which options vest according to their terms, and (ii) 30,064 shares of common stock held directly.